PLCL1: A Drug Target / Disease Biomarker (G5334)

Target Name: PLCL1

NCBI ID: G5334

PLCL1

PLCL1: A Drug Target / Disease Biomarker

PLCL1, also known as CD28, is a protein that is expressed in many different tissues throughout the body, including the immune system, gastrointestinal tract, and skin. It is a member of the B7 family of cytokines, which are a group of proteins that play a critical role in cell signaling.

PLCL1 is highly expressed in many types of cancer, including lung, breast, and ovarian cancer. It has also been shown to be involved in the development and progression of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

One of the key functions of PLCL1 is its role in cell signaling. It is a negative regulator of the T-cell receptor (TCR), which is a protein that plays a critical role in the immune response. PLCL1 helps to ensure that T cells do not become too active and cause unnecessary damage to the body.

In addition to its role in cell signaling, PLCL1 is also a potential drug target. Researchers have shown that inhibiting PLCL1 can be an effective way to treat certain types of cancer, including lung and breast cancer.

One of the reasons why PLCL1 is a promising drug target is its location on the body. It is expressed in many different tissues throughout the body, which makes it an attractive target for drugs that can be administered to a wide range of cells. This can make it easier to find drugs that work against PLCL1 and avoid the potential side effects of those drugs.

Another reason why PLCL1 is a promising drug target is its role in the development and progression of certain diseases. For example, studies have shown that high levels of PLCL1 are associated with an increased risk of developing multiple sclerosis, an autoimmune disease. Additionally, PLCL1 has been shown to be involved in the development of certain types of cancer, including lung and breast cancer.

Finally, PLCL1 is also a promising drug target because it is relatively easy to target. Its structure is well-characterized, and there are a number of small molecules that have been shown to be effective against PLCL1. Additionally, because PLCL1 is expressed in many different tissues throughout the body, it is relatively easy to determine which tissues are being affected by a particular drug.

In conclusion, PLCL1 is a protein that is expressed in many different tissues throughout the body and is involved in the immune response. It is also a negative regulator of the T-cell receptor and has been shown to be involved in the development and progression of certain diseases. As a result, PLCL1 is a promising drug target for the treatment of a wide range of conditions, including cancer and autoimmune diseases.

Protein Name: Phospholipase C Like 1 (inactive)

Functions: Involved in an inositol phospholipid-based intracellular signaling cascade. Shows no PLC activity to phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol. Component in the phospho-dependent endocytosis process of GABA A receptor (By similarity). Regulates the turnover of receptors and thus contributes to the maintenance of GABA-mediated synaptic inhibition. Its aberrant expression could contribute to the genesis and progression of lung carcinoma. Acts as an inhibitor of PPP1C

The "PLCL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLCL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets